Berlin: Bayer has announced the initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha ...

Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome resulting from lipid metabolic imbalance.

hepatocellular adenoma, and hepatic cysts. The affected population usually consists of young women. Clinical management should take into account the symptoms, history, hormonal status (present and ...

SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver ...

Pilatus Biosciences Publishes Preclinical Data in Cancer Discovery on PLT012 First-in-Class CD36-Targeting Antibody for Liver ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome resulting from lipid metabolic imbalance.

A new study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses.

Hepatocellular carcinoma (HCC ... the decision to proceed with LT depends on several factors, including tumor characteristics and the availability of donor organs. This review updates the current ...